EGFR inhibition as a therapy for head and neck squamous cell carcinoma.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Expert Opinion on Investigational Drugs

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/13543784.17.10.1517 PMID 18808311
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.

  2008cited by this paper
• KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

  2008cited by this paper
• EGFR antagonists in cancer treatment.

  2008cited by this paper
• Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma

  2008cited by this paper
• Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer.

  2007cited by this paper
• Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib.

  2007cited by this paper
• Pilot Study of Neoadjuvant Treatment with Erlotinib in Nonmetastatic Head and Neck Squamous Cell Carcinoma

  2007cited by this paper
• Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck.

  2007cited by this paper
• Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer

  2007cited by this paper
• Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity

  2007cited by this paper
• Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck

  2007cited by this paper
• Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.

  2007cited by this paper
• Targeting BRAF in thyroid cancer

  2007cited by this paper
• Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy

  2007cited by this paper
• Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study.

  2007cited by this paper
• SnapShot: EGFR signaling pathway.

  2007cited by this paper
• Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer.

  2007cited by this paper
• Epidermal growth factor receptor targeting in cancer.

  2006cited by this paper
• Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma.

  2006cited by this paper
• Molecular and Cytogenetic Subgroups of Oropharyngeal Squamous Cell Carcinoma

  2006cited by this paper
• Signaling via ErbB2 and ErbB3 Associates with Resistance and Epidermal Growth Factor Receptor (EGFR) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells

  2006cited by this paper
• Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck

  2006cited by this paper
• Epidermal growth factor receptor biology in head and neck cancer.

  2006cited by this paper
• Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

  2006cited by this paper
• Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

  2006cited by this paper
• Chemo-radiotherapy in head and neck cancer.

  2006cited by this paper
• Gefitinib (ZD1839, Iressa™) as palliative treatment in recurrent or metastatic head and neck cancer

  2006cited by this paper
• Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting

  2006cited by this paper
• Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

  2006cited by this paper
• Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.

  2006cited by this paper
• Biological and clinical implications of EGFR mutations in lung cancer

  2006cited by this paper
• EGF–ERBB signalling: towards the systems level

  2006cited by this paper
• Somatic Mutations of EGFR Gene in Squamous Cell Carcinoma of the Head and Neck

  2005cited by this paper
• Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.

  2005cited by this paper
• Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.

  2005cited by this paper
• HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum.

  2005cited by this paper
• Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.

  2005cited by this paper
• Expression of protein tyrosine kinases in head and neck squamous cell carcinomas.

  2005cited by this paper
• Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.

  2005cited by this paper
• Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

  2005cited by this paper
• Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.

  2005cited by this paper
• Biological significance of c-erbB family oncogenes in head and neck cancer

  2005cited by this paper
• Quantitative Determination of Nuclear and Cytoplasmic Epidermal Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer by Using Automated Quantitative Analysis

  2005cited by this paper
• Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

  2005cited by this paper
• Response of Some Head and Neck Cancers to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors May Be Linked to Mutation of ERBB2 rather than EGFR

  2005cited by this paper
• A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter.

  2005cited by this paper
• Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients.

  2005cited by this paper
• Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.

  2005cited by this paper
• ERBB receptors and cancer: the complexity of targeted inhibitors

  2005cited by this paper
• Cisplatinum and Bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial

  2004cited by this paper
• An Epidermal Growth Factor Receptor Intron 1 Polymorphism Mediates Response to Epidermal Growth Factor Receptor Inhibitors

  2004cited by this paper
• Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.

  2004cited by this paper
• Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients.

  2004cited by this paper
• Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

  2004cited by this paper
• Signaling through the epidermal growth factor receptor during the development of malignancy.

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck

  2003cited by this paper
• Constitutive activation of Stat5b contributes to carcinogenesis in vivo.

  2003cited by this paper
• Distinct site-specific oncoprotein overexpression in head and neck squamous cell carcinoma: a tissue microarray analysis.

  2003cited by this paper
• Epidermal growth factor family receptors and inhibitors: radiation response modulators.

  2003cited by this paper
• Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.

  2003cited by this paper
• Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma.

  2003cited by this paper
• Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.

  2002cited by this paper
• Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer.

  2001cited by this paper
• Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling.

  2001cited by this paper
• Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

  2001cited by this paper
• Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.

  2001cited by this paper
• Cutaneous side‐effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225

  2001cited by this paper
• Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer.

  2001cited by this paper
• The EGF receptor - an essential regulator of multiple epidermal functions.

  2000cited by this paper
• Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression.

  2000cited by this paper
• In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody.

  2000cited by this paper
• Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo.

  2000cited by this paper
• The EGF receptor family as targets for cancer therapy

  2000cited by this paper
• Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

  2000cited by this paper
• Combined Modality Therapy of A431 Human Epidermoid Cancer Using Anti-EGFr Antibody C225 and Radiation

  1999cited by this paper
• Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas.

  1999cited by this paper
• Normalization of EGFR mRNA levels following restoration of wild-type p53 in a head and neck squamous cell carcinoma cell line.

  1998cited by this paper
• Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival.

  1998cited by this paper
• Differences in expression of oncogenes and tumor suppressor genes in different sites of head and neck squamous cell.

  1998cited by this paper
• Head and neck cancer: a global perspective on epidemiology and prognosis.

  1998cited by this paper
• Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck.

  1997cited by this paper
• The effect of ionizing radiation on signal transduction: antibodies to EGF receptor sensitize A431 cells to radiation.

  1996cited by this paper
• High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma.

  1996cited by this paper
• MYC amplification in squamous cell carcinomas of the head and neck.

  1996cited by this paper
• Standard chemotherapy in squamous cell head and neck cancer: what we have learned from randomized trials.

  1994cited by this paper
• A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.

  1994cited by this paper
• Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis.

  1994cited by this paper
• The incidence of p53 mutations increases with progression of head and neck cancer.

  1993cited by this paper
• Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer.

  1993cited by this paper
• Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer.

  1993cited by this paper
• Prevalence of RAS oncogene mutation in head and neck carcinomas.

  1992cited by this paper
• Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas

  1991cited by this paper
• The EGF/TGF alpha receptor in skin.

  1990cited by this paper
• Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity.

  1980cited by this paper

• Mechanism of Curcumin in Inhibiting Proliferation of Head and Neck Squamous Cell Carcinoma: A Network Pharmacology and Cellular Experimental Study

  2025cites this paper
• The involvement of epidermal growth factor receptor/protein kinase B signaling in the tumor intrinsic PD-L1-induced malignant potential of oral squamous cell carcinoma.

  2024cites this paper
• Efficacy and Safety of Nimotuzumab in Combination with Radiotherapy or Chemoradiotherapy for Local Advanced Head and Neck Cancer: A Systematic Review and Meta-analysis.

  2024cites this paper
• Advances in radiotherapy and immunity in hepatocellular carcinoma

  2023cites this paper
• Epidermal growth factor/epidermal growth factor receptor signaling blockage inhibits tumor cell‐derived exosome uptake by oral squamous cell carcinoma through macropinocytosis

  2021cites this paper
• Loss of CPAP causes sustained EGFR signaling and epithelial-mesenchymal transition in oral cancer

  2021cites this paper
• EPS8 phosphorylation by Src modulates its oncogenic functions

  2020cites this paper
• Molecular biology of oral cavity squamous cell carcinoma.

  2020cites this paper
• EPS8 phosphorylation by Src modulates its oncogenic functions

  2020cites this paper
• Mitochondrial ROS1 Increases Mitochondrial Fission and Respiration in Oral Squamous Cancer Carcinoma

  2020cites this paper
• ALPK1 Expression Is Associated with Lymph Node Metastasis and Tumor Growth in Oral Squamous Cell Carcinoma Patients.

  2019cites this paper
• Relationship Between EGFR Expression in Oral Cancer Cell Lines and Cetuximab Antibody-dependent Cell-mediated Cytotoxicity

  2019cites this paper
• Contemporary Oral Oncology: Diagnosis and Management

  2018cites this paper
• Eribulin sensitizes oral squamous cell carcinoma cells to cetuximab via induction of mesenchymal-to-epithelial transition

  2016cites this paper
• 2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells

  2016cites this paper
• Emerging Phytochemicals for the Prevention and Treatment of Head and Neck Cancer

  2016cites this paper
• Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer

  2015cites this paper
• MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.

  2015cites this paper
• Loss of epidermal growth factor receptor expression in oral squamous cell carcinoma is associated with invasiveness and epithelial-mesenchymal transition

  2015cites this paper
• Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma

  2015cites this paper
• Phosphorylation of AKT(Ser473) serves as an independent prognostic marker for radiosensitivity in advanced head and neck squamous cell carcinoma

  2015cites this paper
• Loss of EGFR expression in oral squamous cell carcinoma is associated with invasiveness and epithelial-mesenchymal transition

  2015cites this paper
• Axl Mediates Acquired Resistance of Head and Neck Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Erlotinib

  2013cites this paper
• EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.

  2013cites this paper
• Antitumor effects of EGFR antisense guanidine-based peptide nucleic acids in cancer models.

  2013cites this paper
• Regulation of Epidermal Growth Factor Receptor Signaling and Erlotinib Sensitivity in Head and Neck Cancer Cells by miR-7

  2012cites this paper
• Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer

  2012cites this paper
• Flow cytometric cell‐based assay to preselect antibody constructs for radionuclide conjugation

  2012cites this paper
• Bioactive Phytochemical Proanthocyanidins Inhibit Growth of Head and Neck Squamous Cell Carcinoma Cells by Targeting Multiple Signaling Molecules

  2012cites this paper
• Therapeutic targets in head and neck squamous cell carcinoma: identification, evaluation, and clinical translation.

  2012cites this paper
• Phthalocyanine-peptide conjugates for epidermal growth factor receptor targeting.

  2012cites this paper
• Pathway Profiling and Rational Trial Design for Studies in Advanced Stage Cervical Carcinoma: A Review and a Perspective

  2011cites this paper
• An update on molecular diagnostics of squamous and salivary gland tumors of the head and neck.

  2011cites this paper
• Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples.

  2011cites this paper
• EGFR–PI3K–AKT–mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy

  2011cites this paper
• dPORE-miRNA: Polymorphic Regulation of MicroRNA Genes

  2011cites this paper
• Paradoxical effects of T‐cadherin on squamous cell carcinoma: up‐ and down‐regulation increase xenograft growth by distinct mechanisms

  2011cites this paper
• Honokiol Inhibits Epidermal Growth Factor Receptor Signaling and Enhances the Antitumor Effects of Epidermal Growth Factor Receptor Inhibitors

  2010cites this paper
• Pharmacodynamic Trial of Nimotuzumab in Unresectable Squamous Cell Carcinoma of the Head and Neck: A SENDO Foundation Study

  2010cites this paper
• A mouse model for oral squamous cell carcinoma

  2009cites this paper
• Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy.

  2009cites this paper
• Proteins and single nucleotide polymorphisms involved in apoptosis, growth control, and DNA repair predict cisplatin sensitivity in head and neck cancer cell lines.

  2009cites this paper
• Current and potential inflammation targeted therapies in head and neck cancer.

  2009cites this paper